江中药业关于变更审计项目合伙人、签字会计师及质量控制复核人的公告
Filed with SSE · · 2 pages · Chinese
On 6ix: 6ix.com/news/news-51
江中药业股份有限公司(以下简称“公司”)于 2025 年 8 月 20 日召开第十届董事会第七次会议和第十届监事会第七次会议,并于 2025 年 9 月 8 日召开 2025 年第一次临时股东大会,审议通过了《关于续聘 2025 年度审计机构的议案》,同意续聘毕马威华振会计师事务所(特殊普通合伙)(以下简称“毕马威华振”)为公司 2025 年度审计机构,负责本公司年度财务报告审计、内部控制审计及相关专项审计工作(以下简称“本项目”),聘用期为一年。具体内容详见公司于 2025 年 8 月 22 日披露的《江中药业关于续聘 2025 年度审计机构的公告》(2025-041)。 近日,公司收到毕马威华振发来的《关于变更江中药业股份有限公司 2025 年度审计项目合伙人、签字注册会计师及质量控制复核人的函》。现将有关情况公告如下: 一、本次变更项目合伙人及签字注册会计师的情况 毕马威华振原指派项
China Resources Jiangzhong Pharmaceutical Co., Ltd. on 6ix
Earlier from China Resources Jiangzhong Pharmaceutical
- Announcement on Progress in Participating in the Establishment of Double-Crane Pharmaceutical Industry Investment Fund Phase II and Related Party Transactions
- Announcement on the Implementation of Repurchase and Cancellation of Equity Incentive Restricted Stocks
- Announcement on Resolutions of the 8th Meeting of the 10th Board of Supervisors
- Announcement on Convening the Q3 2025 Performance Briefing
- Announcement on Implementation of Semi-annual Dividend Distribution for 2025
Later from China Resources Jiangzhong Pharmaceutical
- Announcement on Lifting of Sales Restrictions and Listing in the 3rd Lifting Period of Initially Granted Portion under the 2021 Restricted Stocks Incentive Plan
- Announcement on Changing Company Name and Stock Abbreviation, Changing Registered Capital, Canceling Board of Supervisors, Amending the "Articles of Association" and Formulating and Revising Corporate Governance Systems
- Announcement on Resolutions of the 11th Meeting of the 10th Board of Directors
- Announcement on Progress in Participating in the Establishment of Double-Crane Pharmaceutical Industry Investment Fund Phase II and Completion of Fund Filing
- Indicative Announcement on Changing Company Name, Completing Industrial and Commercial Change Registration and Changing Stock Abbreviation
Follow China Resources Jiangzhong Pharmaceutical into a list and get an email when it puts out news.
Follow China Resources Jiangzhong Pharmaceutical